Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
// Jonathan M. Gerber 1,* , Jessica L. Gucwa 2,* , David Esopi 2 , Meltem Gurel 2 , Michael C. Haffner 2 , Milada Vala 2 , William G. Nelson 2 , Richard J. Jones 2 , and Srinivasan Yegnasubramanian 2 1 Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 2 The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, USA * These authors contributed equally to this work. Correspondence: Srinivasan Yegnasubramanian, email: // Keywords : chronic myeloid leukemia, CML, leukemic stem cell, LSC, normal hematopoietic stem cell, HSC, myeloid progenitor cells, CD34, CD38, ALDH, IL2RA, CD25, DPP4, CD26, GAS2 Received : April 19, 2013 Accepted : May 5, 2013 Published : May 6, 2013 Abstract The persistence leukemia stem cells (LSCs) in chronic myeloid leukemia (CML) despite tyrosine kinase inhibition (TKI) may explain relapse after TKI withdrawal. Here we performed genome-wide transcriptome analysis of highly refined CML and normal stem and progenitor cell populations to identify novel targets for the eradication of CML LSCs using exon microarrays. We identified 97 genes that were differentially expressed in CML versus normal stem and progenitor cells. These included cell surface genes significantly upregulated in CML LSCs: DPP4 (CD26), IL2RA (CD25), PTPRD , CACNA1D , IL1RAP , SLC4A4 , and KCNK5 . Further analyses of the LSCs revealed dysregulation of normal cellular processes, evidenced by alternative splicing of genes in key cancer signaling pathways such as p53 signaling (e.g. PERP , CDKN1A ), kinase binding (e.g. DUSP12 , MARCKS ), and cell proliferation (e.g. MYCN , TIMELESS ); downregulation of pro-differentiation and TGF-β/BMP signaling pathways; upregulation of oxidative metabolism and DNA repair pathways; and activation of inflammatory cytokines, including CCL2 , and multiple oncogenes (e.g. CCND1 ). These data represent an important resource for understanding the molecular changes in CML LSCs, which may be exploited to develop novel therapies for eradication of these cells and to achieve cure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
A Direct Approach to False Discovery Rates
Storey, J. D. (2002) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00346 · Cited by 5,603
KEGG for integration and interpretation of large-scale molecular data sets
Kanehisa, M., Goto, S., Sato, Y., Furumichi, M., & Tanabe, M. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr988 · Cited by 4,848
Copland, M., Hamilton, A., Elrick, L. J., Baird, J. W., Allan, E. K., Jordanides, N., Barow, M., Mountford, J. C., & Holyoake, T. L. (2006) · Blood · doi:10.1182/blood-2005-07-2947 · Cited by 635 · cited 2×
“LSCs appear to persist in most CML patients on TKIs, and the persistence of these cells remains a major obstacle to cure.[5, 7, 9] We previously reported that ALDH expression enriched for CD34+CD38- cells capable of engrafting NSG mice from normal marrow[18] as well as CML[20], thus, presumably representing the primit…”
BackgroundFlaherty, K. T., LoRusso, P. M., DeMichele, A., Abramson, V. G., Courtney, R., Randolph, S. S., Shaik, M. N., Wilner, K. D., O'Dwyer, P. J., & Schwartz, G. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0509 · Cited by 366 · cited 3×
“The top upstream regulator molecules showed activation of several oncogenes, such as MYC, TBX2, and CCND1, and inflammatory chemokines, such as CCL2 and CXCL2, and inhibition of several tumor suppressors, including TP53 and CDKN2A (Figure 4A, excluding “chemical”-related and “other” upstream molecule types; Supplement…”
BackgroundSchwartz, G. K., LoRusso, P. M., Dickson, M. A., Randolph, S. S., Shaik, M. N., Wilner, K. D., Courtney, R., & O'Dwyer, P. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.177 · Cited by 260 · cited 3×
“The top upstream regulator molecules showed activation of several oncogenes, such as MYC, TBX2, and CCND1, and inflammatory chemokines, such as CCL2 and CXCL2, and inhibition of several tumor suppressors, including TP53 and CDKN2A (Figure 4A, excluding “chemical”-related and “other” upstream molecule types; Supplement…”
BackgroundBarreyro, L., Will, B., Bartholdy, B., Zhou, L., Todorova, T. I., Stanley, R. F., Ben-Neriah, S., Montagna, C., Parekh, S., Pellagatti, A., et al. (2012) · Blood · doi:10.1182/blood-2012-01-404699 · Cited by 201
Cited by
Bachanova, V., Cooley, S., Defor, T. E., Verneris, M. R., Zhang, B., McKenna, D. H., Curtsinger, J., Panoskaltsis-Mortari, A., Lewis, D., Hippen, K., et al. (2014) · Blood · doi:10.1182/blood-2013-10-532531 · Cited by 435
Giustacchini, A., Thongjuea, S., Barkas, N., Woll, P. S., Povinelli, B. J., Booth, C. A. G., Sopp, P., Norfo, R., Rodriguez-Meira, A., Ashley, N., et al. (2017) · Nature Medicine · doi:10.1038/nm.4336 · Cited by 403
Pradella, D., Naro, C., Sette, C., & Ghigna, C. (2017) · Molecular Cancer · doi:10.1186/s12943-016-0579-2 · Cited by 326
Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia
Herrmann, H., Sadovnik, I., Cerny-Reiterer, S., Rülicke, T., Stefanzl, G., Willmann, M., Hoermann, G., Bilban, M., Blatt, K., Herndlhofer, S., et al. (2014) · Blood · doi:10.1182/blood-2013-10-536078 · Cited by 223
BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
Loscocco, F., Visani, G., Galimberti, S., Curti, A., & Isidori, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00939 · Cited by 120
Metadata
- Authors
- Gerber, J. M., Gucwa, J. L., Esopi, D., Gurel, M., Haffner, M. C., Vala, M., Nelson, W. G., Jones, R. J., & Yegnasubramanian, S.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2013-05-06
- Volume
- 4
- Issue
- 5
- Pages
- 715-728
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1841276786
- Cited by
- 107
- References
- 7
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations. https://app.cochat.ai/papers/10.18632/oncotarget.990
- The paper
- Gerber, J. M., Gucwa, J. L., Esopi, D., Gurel, M., Haffner, M. C., Vala, M., Nelson, W. G., Jones, R. J., & Yegnasubramanian, S. (2013). Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations. Oncotarget. https://doi.org/10.18632/oncotarget.990
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.